Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy

  • Yuedong Guo
  • , Ping Hu*
  • , Jianlin Shi*
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

82 Scopus citations

Abstract

Although immunotherapy is relatively effective in treating hematological malignancies, their efficacy against solid tumors is still suboptimal or even noneffective presently. Compared to hematological cancers, solid tumors exhibit strikingly different immunosuppressive microenvironment, severely deteriorating the efficacy of immunotherapy: (1) chemical features such as hypoxia and mild acidity suppress the activity of immune cells, (2) the pro-tumorigenic domestication of immune cells in the microenvironment within the solid tumors further undermines the effectiveness of immunotherapy, and (3) the dense physical barrier of solid tumor tissues prevents the effective intratumoral infiltration and contact killing of active immune cells. Therefore, we believe that reversing the immunosuppressive microenvironment are of critical priority for the immunotherapy against solid tumors. Due to their unique morphologies, structures, and compositions, nanomedicines have become powerful tools for achieving this goal. In this Perspective, we will first briefly introduce the immunosuppressive microenvironment of solid tumors and then summarize the most recent progresses in nanomedicine-based immunotherapy for solid tumors by remodeling tumor immune-microenvironment in a comprehensive manner. It is highly expected that this Perspective will aid in advancing immunotherapy against solid tumors, and we are highly optimistic on the future development in this burgeoning field.

Original languageEnglish
Pages (from-to)10217-10233
Number of pages17
JournalJournal of the American Chemical Society
Volume146
Issue number15
DOIs
StatePublished - 17 Apr 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy'. Together they form a unique fingerprint.

Cite this